Haddad, A.J.; Hachem, R.Y.; Moussa, M.; Jiang, Y.; Dagher, H.R.; Chaftari, P.; Chaftari, A.-M.; Raad, I.I.
Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients. Cancers 2024, 16, 1055.
https://doi.org/10.3390/cancers16051055
AMA Style
Haddad AJ, Hachem RY, Moussa M, Jiang Y, Dagher HR, Chaftari P, Chaftari A-M, Raad II.
Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients. Cancers. 2024; 16(5):1055.
https://doi.org/10.3390/cancers16051055
Chicago/Turabian Style
Haddad, Andrea J., Ray Y. Hachem, Mohamed Moussa, Ying Jiang, Hiba R. Dagher, Patrick Chaftari, Anne-Marie Chaftari, and Issam I. Raad.
2024. "Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients" Cancers 16, no. 5: 1055.
https://doi.org/10.3390/cancers16051055
APA Style
Haddad, A. J., Hachem, R. Y., Moussa, M., Jiang, Y., Dagher, H. R., Chaftari, P., Chaftari, A. -M., & Raad, I. I.
(2024). Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients. Cancers, 16(5), 1055.
https://doi.org/10.3390/cancers16051055
